Sol-Gel Technologies Ltd.
For the period ended Sep 4, 2025. Filed Sep 4, 2025.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Sep 4, 2025 · Filed Sep 4, 2025
Use the contents to explore the available documents and sections.
Contents
Explanatory Note
On September 4, 2025, Sol-Gel Technologies Ltd. (the “Company”) issued a press release announcing Health Canada Approval of EPSOLAY®.
Attached hereto is the following exhibit:
| Exhibit 99.1 | Press release dated September 4, 2025 |
|---|
The first and second paragraphs of Exhibit 99.1 is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (Registration Nos. 333-223915, 333-270477 and 333-286820) and its Registration Statement on Form F-3 (Registration No 333-286822).
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.